Patients with a genetic syndrome called NF2-related schwannomatosis (NF2-SWN) have tumors that develop on the covering of the brain or grow along the nerves in the brain, spinal cord, and/or other locations in the body.
Jun 24, 2024
0
18
Rita Fior, leader of the Cancer Development and Innate Immune Evasion Group at the Champalimaud Foundation (CF), has been studying for several years the power of zebrafish "avatars," or zAvatars, of cancer patients to help ...
Jun 6, 2024
0
20
Traditional chemotherapy often poses significant challenges, including severe side effects, damage to healthy tissue and limited efficacy.
Jun 6, 2024
0
58
A drug approved to treat eczema provided significant improvement in the symptoms of patients with severe itching diseases that currently have no targeted treatments, according to a study published in JAMA Dermatology.
Jun 6, 2024
0
42
Deep brain stimulation (DBS) has shown promise as a treatment for some symptoms of Parkinson's disease (PD). However, not all symptoms improve equally well with DBS. A better understanding of how different sites of electrical ...
Jun 4, 2024
0
33
A recent study has introduced a novel method combining nano informatics and machine learning to precisely predict cancer cell behaviors, enabling the identification of cell subpopulations with distinct characteristics like ...
May 29, 2024
0
38
In a study published in Nature Communications, scientists have made significant strides in understanding the complex interplay between the immune system and cancer metabolism in breast cancer treatment. The research offers ...
May 27, 2024
0
24
The U.S. Food and Drug Administration has expanded indications for AbbVie's Rinvoq (upadacitinib) to now include pediatric patients (ages 2 years and older) with polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic ...
Jun 24, 2024
0
0
A new research perspective titled "When does a melanoma metastasize? Implications for management" has been published in Oncotarget.
Jun 18, 2024
0
0
Lebrikizumab is associated with sustained effects for moderate-to-severe atopic dermatitis for up to week 52 following withdrawal of treatment, according to a study presented at the annual Revolutionizing Atopic Dermatitis ...
Jun 18, 2024
0
0
